Mr. Van Nostrand has served on our board of directors since January 2014. Mr. Van Nostrand was Executive Vice President and Chief Financial Officer of Aureon Biosciences, Inc., a private pathology life science company, from January 2010 to July 2010. Prior to joining Aureon Biosciences, Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc., a private biotechnology company, from July 2007 to September 2008 when the company was acquired. From May 2005 to July 2007, Mr. Van Nostrand served as the Senior Vice President and Chief Compliance Officer of OSI Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he previously served as Vice President and Chief Financial Officer from December 1996 through May 2005 and as Vice President, Finance and Administration prior to that. He also served as OSI's Treasurer from March 1992 to May 2005 and Secretary from March 1995 to January 2004. Mr. Van Nostrand joined OSI as Controller and Chief Accounting Officer in September 1986. Prior to joining OSI, Mr. Van Nostrand served in a managerial position with the accounting firm, Touche Ross & Co., currently Deloitte. Mr. Van Nostrand serves as chairman of the board of directors of Metabolix, Inc., a publicly-traded biotechnology company, as well as chairman of its audit committee. Mr. Van Nostrand also serves on the board of directors of Achillion Pharmaceuticals, Inc., a publicly-traded biotechnology company, where he serves as chairman of the audit committee. He also serves on the board of directors of the Biomedical Research Alliance of New York, a private company providing clinical trial services. Mr. Van Nostrand was the former chairman of, and serves on, the board of the New York Biotechnology Association and serves on the Foundation Board of Farmingdale University. Previously, Mr. Van Nostrand served on the board of directors of Apex Bioventures, Inc., a special purpose acquisition company focused on life sciences. Mr. Van Nostrand holds a B.S. in Accounting from Long Island University, New York. He is a Certified Public Accountant.
What is Robert L. Van Nostrand's net worth?
The estimated net worth of Robert L. Van Nostrand is at least $808,630.50 as of June 18th, 2024. Mr. Van Nostrand owns 9,690 shares of Intra-Cellular Therapies stock worth more than $808,631 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Van Nostrand may own. Learn More about Robert L. Van Nostrand's net worth.
How do I contact Robert L. Van Nostrand?
Has Robert L. Van Nostrand been buying or selling shares of Intra-Cellular Therapies?
Robert L. Van Nostrand has not been actively trading shares of Intra-Cellular Therapies over the course of the past ninety days. Most recently, Nostrand Robert L. Van sold 20,000 shares of the business's stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $75.91, for a transaction totalling $1,518,200.00. Following the completion of the sale, the director now directly owns 9,690 shares of the company's stock, valued at $735,567.90. Learn More on Robert L. Van Nostrand's trading history.
Who are Intra-Cellular Therapies' active insiders?
Are insiders buying or selling shares of Intra-Cellular Therapies?
During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 697,694 shares worth more than $49,905,719.27. The most recent insider tranaction occured on December, 4th when CEO Sharon Mates sold 51,000 shares worth more than $4,375,800.00. Insiders at Intra-Cellular Therapies own 2.6% of the company.
Learn More about insider trades at Intra-Cellular Therapies. Information on this page was last updated on 12/4/2024.
